Skip to content
Search AI Powered

Latest Stories

Videos

Cannabis Cultivation for Big Brands with Posibl | The Edge presented by The Bluntness
Bluntness Media
Exclusives

The Edge: Jesus Burrola on the Intensity of Cannabis Success

The Edge is a special video series presented by The Bluntness, featuring thought-provoking conversations with leaders and innovators throughout the cannabis industry.

In this episode, we were joined by Jesus Burrola, longtime cannabis advocate and CEO of POSIBL. With 15 years of experience in publicly traded building materials distribution, Burrola worked his way up from trainee to VP, and now he’s maneuvered his way into cannabis.


Known as the “cannabis farm of the future,” POSIBL leverages a state-of-the-art system that uses less to do more, bringing the best greenhouse technology and expertise from traditional agriculture into cannabis, and pairing it with the best possible genetics to produce perfect flower every time.

The Bluntness and Burrola discussed sustainable practices, cannabis-infused beverages,and the most surprising challenges of the industry.

The Bluntness Sits Down With POSIBL CEO Jesus Burrola

Burrola first came to POSIBL with a wealth of experience in distribution, and a major fascination with the cannabis industry.

“[Cannabis] is an industry I was fascinated with. I obviously saw the tremendous growth and opportunity in the industry, and it was something I could leave my mark on,” Burrola said.

Just as he worked his way up from trainee to VP in the distribution world, Burrola quickly went from cannabis industry novice to CEO, where he and his team grow for 13 major cannabis brands throughout California.

“We also have a large construction project that is underway. We’re in the process of expanding another 100,000 square feet, along with new processing capabilities and getting into the extraction world,” Burrola said.

His role is to oversee every aspect of the business, while also recognizing these continued opportunities for growth and ensuring his team is happy, comfortable, and equipped with the tools they need to expand.

When asked about the company culture at POSIBL, the word “intense” came quickly to Burrola’s mind.

“It’s one of a lot of hard work and dedication. I do think that we’ve put together a fantastic team: very different backgrounds, from Wall Street banking, to guys that have spent 30 years in agricultural production, to compliance experts,” Burrola said.

“Everybody comes to this industry with very diverse backgrounds, but everyone has a very defined area of focus. I think we work very well together, and a lot of decisions are made as a team.”

Burrola on Cann Beverages, THC During Work Hours, and Jumping Through Industry Hoops

POSIBL’s focus is on pure, sustainable flower, which is arguably the building block of any cannabis product on the market. His team’s incredible work results in a variety of outcomes, from eighths to edibles and everything in between.

The cannabis industry has so many different types of consumers, and POSIBL provides the foundation to keep everyone happy with their consumption method of choice.

One of Burrola’s favorite cannabis products ever? Infused beverages.

“I love Cann. I drink them almost daily. I think they’re social, they’re fun, they’re healthy,” Burrola said.

Although consuming cannabis is a daily ritual for Burrola – and many others in the industry – that daily tradition doesn’t come until after work hours for the CEO, especially when super high levels of THC are involved.

“For me, it’s post work hours. I like to be sharp in making decisions, and for me, I enjoy it when I know that I don’t have very pressing and important decisions to analyze,” Burrola said.

Perhaps Burrola’s answer would change in regards to another industry, but one of the most surprising things he discovered when he first began working in cannabis is how incredibly challenging it actually is.

He isn’t the first industry expert to admit this. Just as cannabis consumers have long been followed by the tired old “lazy stoner” stigma, the industry itself is plagued with this false preconception that no one actually does any work in weed. 

This couldn’t be further from the truth.

“Obviously [the industry] is gaining more and more acceptance, but with regulations changing day in and day out and the inconsistencies in how to handle that,” Burrola said. 

“I was surprised at how difficult simple things like writing a check or making a deposit can be. You’ve got to be prepared to go through a lot of headaches.”

The Importance of Proper Dosage, Staying Curious in Cannabis, and His First Experience With Weed

Burrola is right to say the industry (and the plant itself) is gaining more acceptance as the years go by, but many non-consumers are still wary of cannabis due to the decades of anti-weed propaganda that’s been consistently force-fed to society. 

To those who remain hesitant, Burrola asks that the importance of proper dosage not be underestimated.

“Dose is important. I think if I tried to drink a bottle of vodka the first time I drank, I probably wouldn’t have had a very good experience, and I probably wouldn’t have wanted to drink much after that,” Burrola said.

“You’ve got to really get comfortable with your dosing to have a good experience. Less is more, initially.”

It takes a lot of time and dedication to truly become familiarized with the ins and outs of cannabis, from terpene profiles to cannabinoid makeup to indica versus sativa versus hybrid. And for as much as there is to learn as a consumer, there’s even more to learn as an industry operator.

When asked who his cannabis hero is from past or present – someone who really helped Burrola understand the industry – greenhouse consultant and expert Eric Brandstad immediately came to mind. 

“[He] came and did some consulting with us, and I learned a lot about the plant through him,” Burrola said. 

“I did not come from a cultivation background myself, so really getting those layman’s terms, in a simplified way, of how to understand the plant was really important.”

Although Burrola had a long way to go with cultivation knowledge when he got his start in the industry, he was already quite familiar with the basics of consuming cannabis.

He recalled his first time smoking weed – at age 19 in Colorado, out of a pipe.

“I grew up in Mexico, and it’s very stigmatized there because it’s tied to the cartel. It was very scary and taboo,” Burrola said.

“So, it was in the States through a friend’s dad, which I thought was the strangest thing that could have happened. I thought I was being pranked on camera or something.”

Need a little more Bluntness in your life? Sign Up for our newsletter to stay in the loop.

Up Next

Image of Pennsylvania State Capitol plaque in front of the PA State Capitol.
PA House Pushes Forward with State-Operated Marijuana Stores
Photo by Katherine McAdoo on Unsplash
News

PA Proposes State Cannabis Stores

House Democrats fast-track controversial cannabis bill as state weighs unprecedented regulatory model — but GOP-controlled Senate remains a major hurdle.

Pennsylvania just lit a match under its long-simmering marijuana legalization debate — and this time, it could go up in smoke or spark something entirely new.

On Tuesday, in a razor-thin 102-101 vote, the Pennsylvania House of Representatives advanced House Bill 1200, a cannabis legalization proposal with a twist: sales would flow through state-run stores, mimicking the Commonwealth’s alcohol distribution system. If passed, Pennsylvania would become the first state in the U.S. to fully legalize marijuana and control its retail sales through a government-run operation.

The bill, championed by Democratic Reps. Rick Krajewski and Dan Frankel, rocketed through committee and floor votes in less than 72 hours — a pace that has Republicans crying foul and Democrats defending years of stakeholder engagement.

“This has been a transparent process,” said Frankel, who chairs the House Health Committee. “My door has been open for two years. We’ve held six hearings. The GOP knew this was coming.”

Still, Republicans aren’t buying it. “It’s being rammed through,” charged Rep. Charity Grimm Krupa, one of several GOP lawmakers voicing concerns over workplace safety, impaired driving, and the state’s potential overreach.

A Bold — and Controversial — Model

What makes HB 1200 a national outlier isn’t just its swift advancement — it’s the regulatory vision it puts forward.

Rather than opening the floodgates to private cannabis entrepreneurs, the bill would put the Pennsylvania Liquor Control Board (LCB) in charge of both licensing and operating cannabis stores. LCB would also oversee cultivation, processing, transportation, and consumption lounges — many of which could still be privately owned.

Adults 21 and over could legally purchase up to 42.5 grams of cannabis per day from LCB stores. Possession of small amounts beyond that would be decriminalized, while home growers could cultivate up to four plants (two mature, two immature) with a $100 permit.

Taxes would include a 12% excise rate on retail sales, with revenue feeding into a Cannabis Revenue Fund. That fund would support everything from expungement efforts and addiction services to minority business development and local court systems.

But it’s the state-store concept that’s drawing fire — not just from Republicans, but even some Democrats and the public.

A recent poll showed most Pennsylvanians prefer a private business model for cannabis sales. Rep. Abby Major (R), who is drafting an alternative bill alongside Democrat Emily Kinkead, stated bluntly: “There are zero votes for a state-store model in the Republican caucus.”

Progress or Power Play?

Despite the internal divisions, House Speaker Joanna McClinton (D) insists her party is ready to legalize. But with Republicans controlling the Senate, any cannabis bill — especially one this sweeping — will require bipartisan cooperation.

Even among legalization supporters, questions remain. Does a state-run retail model maximize equity and efficiency? Will it stifle entrepreneurship in favor of bureaucratic control? Or could it offer the kind of standardized safety and oversight that other states have struggled to achieve?

Meanwhile, advocates like Karen O’Keefe from the Marijuana Policy Project see a long-overdue opportunity: “It is past time for Pennsylvania to catch up with its neighbors and allow adults to relax with cannabis,” she told Marijuana Moment.

Cannabis Legalization Models: Pennsylvania vs. Neighboring States

Pennsylvania's proposed model, emphasizing state-run retail operations, distinguishes it from neighboring states that have adopted privatized systems. While this approach aims to centralize control and potentially streamline regulation, it faces criticism for potentially stifling private enterprise and raising concerns about federal compliance. In contrast, New York, New Jersey, and Maryland have embraced private-sector models, focusing on social equity and community reinvestment, though each faces unique challenges in implementation and market development.

FeaturePennsylvania (Proposed)New YorkNew JerseyMaryland
Retail ModelState-run stores operated by the Liquor Control BoardPrivately owned dispensaries with state-issued licensesPrivately owned dispensaries with state-issued licensesPrivately owned dispensaries with state-issued licenses
Possession LimitUp to 42.5 grams per dayUp to 3 ounces (approx. 85 grams)Up to 6 ounces (approx. 170 grams)Up to 1.5 ounces (approx. 42.5 grams)
Home CultivationUp to 2 mature and 2 immature plants with a $100 annual permitUp to 6 plants per householdNot permittedUp to 2 plants per household
THC LimitsFlower: max 25% THC; Edibles: 5mg per serving, 25mg totalNo specific THC limitsNo specific THC limitsNo specific THC limits
Taxation12% excise tax; additional 3% local tax for on-site consumption lounges13% combined state and local tax6.625% state sales tax; up to 2% local tax; additional excise fees9% state sales tax; additional local taxes permitted
Social Equity ProgramsLoan and grant programs for applicants with income below 200% of area median income and justice-impacted individualsPrioritization for individuals with past cannabis convictions and those from disproportionately impacted communitiesPrioritization for individuals from economically disadvantaged areas or with past cannabis convictions75% of licenses awarded to minority-owned businesses; strict advertising and packaging regulations to protect youth
Public ConsumptionProhibited; fines ranging from $100 to $200Prohibited in public placesProhibited in public placesProhibited in public places
Employment ProtectionsOff-the-job use protected; exceptions for federally contracted workers and explicit company prohibitionsOff-the-job use protected; exceptions for safety-sensitive positionsOff-the-job use protected; exceptions for safety-sensitive positionsOff-the-job use protected; exceptions for safety-sensitive positions
Implementation StatusPassed House; pending Senate approvalLegalized; implementation ongoing with challenges in licensing and enforcementLegalized; implementation ongoing with over 100 legal stores operatingLegalized; implementation ongoing with focus on minority-owned businesses and public health education

What’s Actually in the Bill?

Here are some of the key provisions of HB 1200:

  • Retail and Licensing: Cannabis would be sold exclusively through state-operated stores. The LCB would license 50 cultivators, processors, and transporters, plus micro-licensees.
  • Possession & Use: Adults could purchase up to 42.5 grams daily. Possession beyond that (up to 3x the limit) would be decriminalized.
  • THC Limits: Flower capped at 25% THC; edibles limited to 5mg per serving, 25mg total.
  • Social Equity: A new loan and grant program for equity applicants, defined by income, community impact, and justice system involvement.
  • Tax Revenue Allocation: 50% to community reinvestment, 10% to treatment, 5% to cannabis business development, 2.5% to minority biz support, 2% to court expungement programs.
  • Employment Protections: Off-the-clock cannabis use can’t be penalized (with some exceptions).
  • Home Grow: Limited to four plants with permit.
  • Public Consumption: Still banned; fines range from $100–$200.

The Road Ahead

While HB 1200's advancement is historic, it’s far from law. Senate Republicans remain cold on legalization altogether, let alone a state-controlled model. Senate Majority Leader Joe Pittman recently said there’s “no consensus” among the four legislative caucuses or with the governor’s office.

Still, Democratic Governor Josh Shapiro has repeatedly called for legalization — though he hasn’t endorsed the state-store concept. In March, he bluntly stated: “Pennsylvanians are driving to other states and paying their taxes.”

It’s a sentiment echoed across the political spectrum. Even some Republican lawmakers admit that prohibition has been a “disaster.” But whether they’re ready to get behind this particular vision remains to be seen.

With neighboring states like New York, New Jersey, and Maryland already enjoying adult-use cannabis markets, Pennsylvania risks being left behind — again. Whether it embraces a public-sector model or a more traditional privatized framework, one thing is clear: legalization is no longer a matter of “if,” but “how.”

This article includes reporting and original source material from Marijuana Moment and journalist Kyle Jaeger.

retail shelves stocked with legal cannabis products
The mix of in-state and out of state brands at a legal NY dispensary
The mix of in-state and out of state brands at a legal NY dispensary
News

NY's Pot Industry: Wins, Woes, Next

Despite crossing $1 billion in sales, New York’s cannabis market reveals a fragile ecosystem where equity ambitions, high taxes, and regulatory drag threaten to blunt its full potential.

Two years into New York's adult-use cannabis rollout, the state's Office of Cannabis Management (OCM) has dropped its most comprehensive look yet at the market's performance, challenges, and opportunities. The 2024 OCM Market Report is packed with impressive numbers and lofty intentions, but peel back the layers and a more complicated story unfolds—one where equity goals face harsh economic headwinds, regulatory delays hamper progress, and a persistent illicit market looms large.

Here's what you need to know:

$1 Billion and Counting: A Sales Surge Worth Celebrating

As of the end of 2024, New York's legal adult-use cannabis market has generated more than $1.02 billion in retail sales, with $869 million of that coming in 2024 alone. The fourth quarter of 2024 shattered records with over $333 million in sales. By April 2025, the number of licensed dispensaries had climbed to 363.

That's no small feat for a state that only began regulated adult-use sales in December 2022. Consumer demand is clearly there—particularly in downstate regions like Manhattan, Queens, and Long Island, which accounted for over 58% of total sales.

But before we light a joint in celebration, let’s take a closer look at the fine print.

graph of NY Cannabis Retail Sales by Quarter 2024New York Cannabis Retail Sales by Quarter - 2024 - The Bluntness

Equity on Paper, But Economic Reality Bites

The MRTA's mandate that 50% of licenses go to social and economic equity (SEE) applicants has technically been met—54% of adult-use licenses were issued to SEE applicants as of December 2024. CAURD licensees, many of whom are justice-involved, make up 70% of all open dispensaries.

Still, the financial picture is grim for many of these operators. Over one-third of dispensaries are generating under $2 million annually—a threshold considered unsustainable in most regions due to high operating costs and steep taxes. Meanwhile, just 10 shops account for 26% of total sales.

2024 New York Market Share by % of Sales - The BluntnessThe Bluntness

Despite fee waivers and state support, the data suggest that equity licensees are struggling to survive, let alone thrive. The state's well-intentioned goals risk being undermined by market dynamics that favor capital-rich players, including the Registered Organizations (ROs) who are already outperforming in terms of sales per location.

Taxation Nation: A Competitive Disadvantage

New York's cannabis tax structure remains a sore spot. With a 13% retail excise tax layered on top of local sales tax and additional THC potency taxes (though now repealed), legal operators face margins that are razor-thin. That gives illicit operators—still prevalent in many parts of the state—a distinct price advantage.

Even with increased enforcement and over 1,500 illicit stores shut down, the black market continues to flourish, undermining legal businesses and depriving the state of much-needed revenue.

License Backlogs, Delays, and Confusion

Licensing delays and litigation have hampered the industry from day one. Although over 1,600 licenses were issued by the end of 2024, only a fraction of them are operational. Many applicants have waited months for updates, even after securing real estate and investing heavily.

OCM's new "single point of contact" model aims to streamline the process, but trust is still being rebuilt. The LOCAL Map tool is a step in the right direction, but many operators still face steep learning curves and a minefield of regulatory compliance.

Consumer Trends: Edibles, Vapes, and Bigger Brands

Flower still leads the way at 33% of sales, but consumer demand is shifting. Vaporizers (28%), edibles (14%), and concentrates (11%) are gaining traction. Price-conscious buyers are gravitating toward value options, particularly ounce-sized packages from ROs, which are cheaper on average than those from adult-use cultivators.

Brand loyalty is starting to emerge, with the top 5 brands accounting for 21% of total sales and the top 20 capturing nearly half. However, over 500 brands are currently in the market, and competition is fierce.

pie chart breaking down marketshare by product category in NY's legal cannabis marketShare of market by product category according to 2024 OCM Report - The Bluntness

Retail Disparity: A Tale of Two Markets

While sales are booming in Downstate regions, the Upstate market tells a different story. Despite having more open dispensaries, Upstate regions only accounted for 42% of reported sales in 2024. Dispensaries in less densely populated areas face longer ramps, higher per-store operating costs, and less customer traffic.

Moreover, while ROs and a handful of high-performing CAURD stores dominate sales, the bottom third of licensees are operating below breakeven. Many SEE licensees are still in limbo due to financing, construction, and municipal zoning delays, putting them at risk of falling behind before they ever open their doors.

What Needs to Happen Next?

The OCM recommends:

  • Continuing to prioritize and support SEE operators with real financial tools.
  • Streamlining the licensing process with more transparency and accountability.
  • Re-evaluating tax policies to make legal products competitive with the illicit market.
  • Encouraging brand diversity and innovation to capture more market share.
  • Strengthening data systems to improve market monitoring and consumer safety.

But recommendations alone won't fix structural issues. If New York wants to fulfill its promise of a socially equitable, thriving cannabis market, it must move faster, regulate smarter, and tax more fairly.

Because if not, the state's billion-dollar baby may never grow up.

Blunt Verdict: Progress, Yes. But Let’s Not Confuse Motion with Momentum.

Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
News

Selective Outrage Hurts NY Cannabis

New York’s cannabis market is at a crossroads. Selective enforcement and public manipulation threaten the very foundation equity was built on. Here’s an analysis of the NYMCIA accusations — and why the entire industry must demand better. Written by Jason Ambrosino, Founder and CEO of Veterans Holdings, a Disabled Veteran-Owned Cannabis Business in New York State.

Authored by: Veterans Holdings CEO Jason Ambrosino

Last week, the New York Medical Cannabis Industry Association (NYMCIA) issued a press release accusing licensed dispensaries of selling "out-of-state cannabis" and undermining the integrity of the legal market. Read the press release here.

Public trust matters. Regulatory compliance matters. But trust is not built through accusations based on incomplete science and selective outrage.

After reviewing the NYMCIA’s claims and the underlying lab report they referenced, it is clear that their conclusions are neither professionally sound nor fairly applied.

NYMCIA’s Real Membership and Interests

NYMCIA is not simply a voice for patients or small businesses. It is a lobbying association for some of the largest multi-state operators (MSOs) in the country, including Curaleaf, Acreage, and Columbia Care.

These same MSOs have:

  • Lobbied aggressively to accelerate their own entry into the adult-use market, cutting short the period intended to prioritize social equity operators.
  • Sued the state to avoid paying the $20 million participation fee designed to fund social equity initiatives.
  • Opposed efforts to allow home grow rights for patients and consumers.

Understanding who is behind NYMCIA’s messaging is critical to understanding the motivations behind their recent press release.

Flaws in the "Proof" Presented

The Lexachrom Analytical Laboratory report cited by NYMCIA relies primarily on isotope ratio mass spectrometry (IRMS) and soil residue analysis. While these scientific tools can provide information about environmental conditions, they cannot definitively determine where a cannabis plant was grown.

Several serious flaws are immediately clear:

  • Isotope markers like δ¹³C, δ¹⁵N, and δ²H are not location GPS markers. They can indicate broad environmental patterns but cannot pinpoint state or origin with certainty.
  • Soil inputs are not static. Commercially available soil brands like FoxFarm, produced in California, are widely sold across the United States. A New York cultivator using FoxFarm soil would logically display “California” markers without engaging in illegal interstate commerce.
  • The lab report itself admits only a "medium-to-high confidence" and recommends further confirmatory testing. Despite this, NYMCIA moved forward with public accusations.

Furthermore, no information about sample collection, chain of custody, or independent peer review has been provided. Without these elements, the claims should not have been treated as definitive.

Selective Enforcement and Curaleaf’s Aqueous Extraction

What makes this situation more troubling is the selective application of scrutiny.

One of NYMCIA’s most prominent members, Curaleaf, is currently producing extracts using an “aqueous extraction” method. While cold-water mechanical separation (ice water hash) is permitted under New York’s regulations, chemically assisted aqueous extraction — involving buffers, acids, or chemical filtrations — raises serious compliance questions.

The Office of Cannabis Management (OCM) has already set a precedent: When Jenny’s cannabis was found to be using an unapproved R134A extraction method, enforcement was swift and decisive, even though that method was later approved.

If enforcement is to be credible, it must be consistent. Curaleaf’s extraction practices should face the same level of regulatory review, not quiet exception.

Article contentOriginal Concept: Jason Ambrosino | Artwork generated via AI Illustration.


Protecting Incumbents vs. Building a Fair Market

By leveraging incomplete science and selectively targeting competitors, NYMCIA risks damaging the legitimacy of the legal cannabis market at a fragile time.

New York's cannabis industry deserves:

  • Transparent, evidence-based enforcement
  • Equal scrutiny for all operators, regardless of size or influence
  • A commitment to building a diverse and equitable marketplace

Weaponizing regulatory narratives to protect large incumbents weakens public trust and undermines the original goals of cannabis legalization.

Conclusion: New York Can Lead, If We Lead With Integrity.

Selective outrage will not build a sustainable market. Selective enforcement will not earn public trust. New York’s cannabis future must be built on transparency, fairness, and consistent regulatory standards.

We must hold ourselves, our trade associations, and our regulators to a higher standard.

The New York cannabis industry has an opportunity to set the national model — but only if we lead with integrity.

If you believe in a transparent, fair cannabis industry, now is the time to speak up. The future of New York's market depends on it.

This article was originally published on LinkedIn and published here with permission.

image of California coast, pacific coast highway at sunset
How Overregulation Crushed California’s Gold Flora—And Why Other States Should Be Worried
Photo by Matthew Hamilton on Unsplash
News

Overregulation Kills Gold Flora

California’s Gold Flora was once a cannabis success story with $100M in annual revenue and 16 dispensaries. Now it’s selling off its assets under court supervision. The real culprit? A brutal cocktail of overregulation, high taxation, and policy missteps. And it’s not just California—other legal markets across the U.S. are showing the same dangerous signs.

When California-based Gold Flora entered the legal cannabis scene, the company was poised to dominate. Backed by serious money and a sprawling, vertically integrated operation—from a 100,000-square-foot cultivation campus in the desert to marquee dispensaries in West Hollywood and San Jose—Gold Flora wasn't just riding the green wave. It was supposed to be the wave.

But by the end of March 2025, the company had filed for receivership, its assets now headed to auction. And while headlines cite "merger woes" and "market conditions," the real culprit behind Gold Flora’s collapse is far more systemic: a regulatory stranglehold that has quietly choked the life out of California’s once-promising cannabis economy.

And California isn't alone. From Colorado to Massachusetts, Michigan to New Jersey, the same pattern is playing out—an industry that was supposed to represent a generational economic boom is buckling under the weight of its own rules.

Legal Cannabis: A Cautionary Tale from the Golden State

Gold Flora’s story reads like a textbook example of how not to build a sustainable cannabis market. Despite $100 million in annual revenue, the company couldn’t outpace its liabilities. Many of those stemmed from its 2023 merger with Jay-Z-backed TPCO—a deal that looked good on paper but brought legal baggage and bloated overhead for the cannabis business.

But let’s be clear: Gold Flora’s real downfall wasn’t bad business. It was bad policy.

California has burdened its legal operators with sky-high taxes, Byzantine licensing processes, and patchwork enforcement that gives illegal players a competitive edge. Cannabis companies, particularly multistate operators, are selective in choosing their operational states due to these macroeconomic challenges. Operators like Gold Flora are expected to run professional, compliant, multimillion-dollar operations—yet they pay a premium for the privilege, all while watching untaxed, unregulated competition thrive. The Department of Cannabis Control's strict regulations and high costs can drive entrepreneurs towards the illegal market.

The state’s refusal to offer any real financial relief, coupled with the federal government’s continued classification of cannabis as a Schedule I drug (which bars companies from bankruptcy protection), makes the situation even more dire. The legal market in California continues to struggle with high taxes and regulatory burdens, despite significant strides since legalization. A court-appointed receiver will now attempt to recoup what they can by liquidating Gold Flora’s assets.

gif of falling dominoes The Dominoes Are Falling Nationwide as Federal Prohibition EndsGiphy

The Dominoes Are Falling Nationwide as Federal Prohibition Ends

The same structural failings are rippling through other legal cannabis markets. The evolving landscape of the adult use cannabis market highlights the importance of regulations and business strategies in various states that have legalized or are considering legalization.

In Colorado, one of the first states to legalize recreational marijuana, wholesale prices have tanked amid oversupply and fierce competition. Cannabis businesses are closing shop at alarming rates, not because demand has waned, but because the math no longer works.

Massachusetts has become infamous for its bureaucratic bottlenecks and licensing delays, particularly impacting smaller and BIPOC-led businesses that were supposed to benefit from the state’s social equity promises. Instead, many are stuck in limbo—burning cash without the ability to operate.

Michigan is facing market saturation without adequate regulation to ensure long-term viability. The result? A race to the bottom on pricing that favors large MSOs (multi-state operators) while squeezing out local entrepreneurs. The medical market also plays a crucial role in the state's cannabis industry dynamics.

New York and New Jersey, the newer members of the adult-use club, have already shown signs of following in California’s footsteps. Despite bold equity-first frameworks, New York’s rollout has been slow and mired in litigation, allowing illicit shops to flourish. Legal operators, many of whom are equity licensees, are struggling to keep the lights on before ever making a sale.

In New Jersey, the licensing backlog and zoning battles have made it nearly impossible for smaller players to launch on time—or at all—while larger corporations move faster through regulatory red tape. The legalization of recreational cannabis has opened up a new customer base, but it also brings complex regulatory challenges and market fluctuations.

But the most absurd—and revealing—comparison lies in how we tax cannabis versus alcohol.

Cannabis Taxes vs. Alcohol Taxes: A Disparity That Defies Logic

Consider this: In Colorado, cannabis taxes raised $396 million in a single year. Alcohol taxes? Just $53 million. That’s nearly 7 times more revenue from cannabis—despite alcohol being more widely consumed and associated with far greater public health costs.

In Massachusetts, cannabis excise taxes brought in $74 million, far outpacing the $51 million generated by alcohol.

Why? Because alcohol is taxed on volume—just 1–2 cents per drink. Cannabis, on the other hand, is often taxed by price, weight, or even THC potency, creating a punitive and volatile tax structure. In New York, cannabis products face a 13% retail tax plus a potency-based excise tax of up to $0.03 per milligram of THC. That’s the equivalent of taxing alcohol based on its ABV—imagine paying more for a strong IPA than a light beer, just because it gets you buzzed faster.

In practice, this means legal cannabis consumers often pay 30%–50% more at checkout due to layered taxes—a major reason why two-thirds of cannabis sales in California still happen in the illicit market.

So while states claim to support legal cannabis, their tax structures say otherwise. They’re bleeding the industry dry while subsidizing its competition.

Overregulation Is Not the Same as Oversight

Let’s be clear: cannabis should be regulated. Cannabis dispensaries play a crucial role in California's evolving market, facing both establishment challenges and regulatory obstacles. But the frameworks emerging across legal states often confuse control with support. Instead of building fertile ground for entrepreneurship, governments have built obstacle courses—stacking taxes, fees, compliance costs, and red tape so high that only the best-capitalized (or luckiest) can survive. Cannabis entrepreneurs initially entered the market with optimism and significant investments, but now face regulatory complexities and market fluctuations.

Ironically, this regulatory overkill is doing the opposite of what it was designed to do. It’s propping up the illicit market. In California, it’s estimated that 2 out of 3 cannabis sales still happen outside the legal system—largely because underground cannabis products are cheaper, more accessible, and often indistinguishable from licensed alternatives to the average consumer.

Federal law creates significant challenges for cannabis businesses, including high operational costs and prohibitive tax rates. Federal prohibition contributes to a fragmented cannabis industry, creating inconsistencies in regulations and increasing operational costs for businesses. The legal operators? They’re not just competing—they’re subsidizing the competition.

Cannabis Industry at a Crossroads

The cannabis industry is not dying—but it is disillusioned. Cultivation operations face significant financial and regulatory challenges, making it difficult for new businesses to thrive. The dream that legalization would automatically lead to prosperity, job creation, and community reinvestment has hit a sobering wall, even as the industry is growing rapidly.

If states want to salvage what’s left of that dream and address the aftermath of efforts to legalize cannabis, they need to shift their approach:

  • Streamline licensing and compliance so smaller, independent operators can enter and stay in the game.
  • Reform cannabis tax structures to bring them more in line with alcohol, making legal products affordable and competitive.
  • Crack down on illicit operators fairly and consistently, instead of using legal businesses as cash cows to fund enforcement.
  • Offer safety nets, such as access to grants, bridge loans, and eventually, bankruptcy protections.
  • Push for federal reform, including bankruptcy protections and fair banking access.

Medical cannabis is also becoming more prevalent, with major companies acquiring dispensaries and retailers across multiple states. Until then, more companies like Gold Flora—once hailed as the future—will quietly implode under the weight of policies that were never built to let them thrive.If Gold Flora—a well-capitalized, vertically integrated company—couldn’t survive under this system, who can?

Until these issues are addressed, more cannabis companies will fall—many quietly, some publicly—but all as casualties of a system that never truly wanted them to succeed.

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Photo by Axel Antas-Bergkvist on Unsplash
News

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen

Kanye West, aka Ye, isn’t just trending—he’s unraveling in real time. And instead of intervention, we get viral clips, condemnation, and an audience watching a man self-destruct. His latest stunt? Airing a Super Bowl ad promoting a swastika-emblazoned Yeezy shirt on his site—a move so blatantly antisemitic that even the most die-hard supporters had to step back. This act garnered significant media coverage, leading to brands cutting ties and agents dropping him. His social media account faced scrutiny and was ultimately deleted after a history of controversial postings. But here’s the problem: canceling Kanye doesn’t fix Kanye.

At this point, the question isn’t whether his actions are inexcusable (they are). The question is, what happens when one of the world’s most influential figures is also one of the most untreated cases of mental illness in pop culture history?

We’ve tried outrage. We’ve tried exile. Maybe it’s time we try science.

Lamar Odom: Kanye West, Using Ketamine and Mental Health Wellness.👀🙌🏾

Lamar Odom speaks about his closeness to Kanye West and the importance of mental heath wellness. #PeoplesParty #MentalHealth

Early Life and Career

Kanye West, an American rapper, was born on June 8, 1977, in Atlanta, Georgia, but it was in Chicago, Illinois, where he truly found his rhythm. Growing up in a household that valued education and creativity, Kanye was influenced by his mother, Donda West, an English professor, and his father, Ray West, a photojournalist. This unique blend of intellectual and artistic stimulation set the stage for his future endeavors.

From a young age, Kanye was drawn to music, and by his teenage years, he was already producing beats and honing his craft. His passion for music was so strong that he decided to drop out of college to pursue it full-time—a decision that would later become a defining part of his identity. As a record producer, Kanye made significant strides at Roc-A-Fella Records, where he produced tracks for heavyweights like Jay-Z and Alicia Keys. His innovative production style quickly garnered attention, setting the foundation for his illustrious career.

Rise to Fame and Debut Album

Kanye West’s big break came in 2004 with the release of his debut album, “The College Dropout.” This album was more than just a collection of songs; it was a statement. With its blend of soulful beats, intricate lyrics, and thought-provoking themes, “The College Dropout” was both a critical and commercial triumph. It catapulted Kanye into the limelight, establishing him as a rising star in the hip-hop world.

But Kanye didn’t stop there. He followed up with albums like “Late Registration” and “Graduation,” each one pushing the boundaries of what hip-hop could be. His innovative production techniques and lyrical depth set him apart from his peers, earning him a reputation as one of the most influential and groundbreaking musicians of his generation. Kanye’s rise to fame wasn’t just about chart-topping hits; it was about redefining the genre and challenging the status quo.

Mental Health Struggles

Kanye West has never shied away from discussing his mental health struggles. Diagnosed with bipolar disorder, Kanye has used his platform to shed light on the complexities of living with mental illness. His openness about his experiences with anxiety and depression has helped to reduce the stigma surrounding mental health issues, making it a topic of public conversation.

Through his music, Kanye has found a way to process and cope with his emotions. Albums like “Ye” and “Kids See Ghosts” offer a raw and unfiltered look into his mental state, providing listeners with a glimpse of his inner turmoil. Despite the challenges he faces, Kanye continues to be a prolific and innovative artist, using his platform to advocate for mental health awareness and support others who may be struggling.

The Case for Psychedelic Therapy—And Why Ye Is a Walking Case Study

Kanye's story isn't just about one man losing control—it's a cautionary tale about the limits of traditional mental health treatments. He was diagnosed with bipolar disorder in 2016, and then in 2025, he claimed he was actually autistic, not bipolar. Whether it's one, the other, or both, one thing is clear: whatever treatment he's received isn't working.

That's where psychedelic therapy comes in.

Clinical research from Johns Hopkins, MAPS, and leading neuroscience labs is proving that psychedelics—psilocybin (magic mushrooms) and MDMA—can be breakthrough treatments for treatment-resistant mental health conditions. And if anyone fits the criteria of treatment-resistant, it's Kanye West.

Here’s why psychedelic therapy could actually help:

The science is there. The therapy is real. The question is, will anyone in Kanye’s circle actually get him the help he needs?

But Let’s Be Clear—None of This Excuses Kanye’s Actions

This isn’t about forgiving Kanye. It’s about understanding why we’re watching the same cycle on repeat: a manic rise, a public breakdown, a media firestorm, and a brief period of silence before it happens all over again.

Make no mistake—his antisemitic rhetoric, his Hitler obsession, his inflammatory rants—they’re not a symptom of mental illness. They’re a symptom of unchecked power, a broken mental health system, and a culture that monetizes celebrity meltdowns instead of addressing them.

So, what do we do? Keep canceling him until there’s nothing left to cancel? Or demand that mental health and accountability exist in the same conversation?

Because here’s the thing—if one of the richest, most powerful celebrities in the world can’t get the right mental health treatment, what hope does anyone else have?

- YouTubewww.youtube.com

Public Perception and Media Coverage

West's personal brand has always been a magnet for media attention and public scrutiny. Known for his outspoken views and willingness to speak his mind, Kanye has often found himself at the center of controversy. His comments on politics, race, and social justice have sparked both backlash and debate, painting him as a divisive figure in the eyes of many.

However, it’s impossible to ignore Kanye’s contributions to music and culture. His innovative approach to production and his commitment to pushing boundaries have earned him praise and admiration. Despite the controversies that often surround him, Kanye remains one of the most influential and innovative artists of his generation. His ability to spark conversation and challenge societal norms ensures that he will continue to be a significant figure in the cultural landscape.

By maintaining the same tone and style, these new sections seamlessly integrate into the existing article, providing a comprehensive look at Kanye West’s life, career, and ongoing struggles with mental health.

Impact on Mental Health Awareness

Kanye West has been a pivotal figure in bringing mental health discussions to the forefront of public consciousness. His candidness about his own struggles with bipolar disorder, anxiety, and depression has not only humanized him but also made mental health a topic of mainstream conversation. By openly sharing his experiences, Kanye has encouraged fans to prioritize their mental well-being and seek help when needed, breaking down barriers of stigma and silence.

Through his music and public appearances, Kanye has consistently highlighted the importance of mental health. Albums like “Ye” and “Kids See Ghosts” offer raw insights into his mental state, making listeners feel less alone in their struggles. His willingness to discuss his vulnerabilities has inspired many to share their own stories, fostering a community of support and understanding.

Beyond his personal advocacy, Kanye has partnered with mental health organizations to amplify their efforts and promote available resources. His influence has significantly increased awareness and understanding of mental health issues, encouraging a culture where seeking help is seen as a strength rather than a weakness.

His legacy as a mental health advocate will hopefully continue to inspire and educate, promoting a culture of mental health awareness and support within the music industry and beyond.

The Bigger Question: Are We Actually Ready to Talk About Real Solutions for the Rapper?

The knee-jerk reaction is easy: "Screw Kanye. He’s beyond saving."

But the hard conversation is this: What if we actually tried a treatment that works?

Psychedelic therapy isn’t just a trippy Silicon Valley trend—it’s being fast-tracked for FDA approval because the data is undeniable. War veterans with PTSD. People with treatment-resistant depression. Survivors of trauma. Psychedelics are doing what years of conventional therapy and pharmaceuticals couldn’t.

So, why not Kanye?

If we can watch a man spiral on the world stage and still refuse to acknowledge that maybe, just maybe, traditional treatments aren’t enough—then maybe we’re the ones who need a reality check.

Sources & Further Reading:

  1. Psychedelic 'Magic Mushroom' Drug May Ease Some Depression – McLean Hospital
  2. Psilocybin for Depression: Breakthrough or Hype? – Johns Hopkins Medicine
  3. MDMA and PTSD: A New Path for Therapy? – MAPS Research Institute
  4. Kanye West Dropped by Talent Agent After Antisemitic Rant – People
  5. Kanye West’s Website Goes Down After Nazi T-shirt Sales – France 24
Disclaimer:

While psychedelic therapy has shown promise for certain mental health conditions, it is not recommended for individuals with bipolar disorder without careful medical supervision. Psychedelics can trigger manic episodes or exacerbate symptoms in some patients. Anyone considering this treatment should consult a licensed medical professional and seek therapies that are FDA-approved and backed by rigorous clinical research.

Recent